Targeting circHIPK2 in macrophages may represent a promising therapeutic strategy for treating inflammatory cardiac conditions and heart failure, potentially leading to the development of RNA-based therapies targeting immune cells in MI treatment.
Jung et al. (Wed,) studied this question.